Recent advances in understanding the relationship between lipid metabolism and immune escape in the tumor microenvironment of gastric cancer.

Gastric cancer (GC), a leading global malignancy, poses a significant threat to human health. Despite substantial therapeutic advances, drug resistance remains a major challenge for many patients. Aberrant lipid metabolism represents a hallmark in tumors; it critically contributes to GC pathogenesis. This review explores key enzymes and pathways driving lipid metabolic reprogramming within the GC immune microenvironment, which facilitates tumor immune evasion and chemotherapy resistance. This review also addresses the challenges posed by lipid metabolism reprogramming in clinical treatment, explores therapeutic perspectives and novel directions, and discusses metabolism-related mechanisms.